Trust Signals
Key Takeaways
- AOD-9604 is a 16-amino-acid synthetic fragment derived from residues 177 to 191 of human growth hormone, with an added N-terminal tyrosine and a molecular weight of approximately 1815.1 Da.
- The compound reached Phase 2 human trials for obesity (Metabolic Pharmaceuticals, early 2000s) but never advanced to Phase 3, leaving overall human efficacy evidence rated Low quality.
- WADA lists AOD-9604 on its Prohibited List (S2 category), making it a banned substance for all competitive athletes under anti-doping jurisdiction.
- A legitimate COA must include an HPLC chromatogram, mass spectrometry confirmation near 1815.1 Da, and endotoxin results, not just a stated purity percentage.
- FDA guidance has flagged AOD-9604 as a bulk substance that may not qualify for 503A compounding, meaning standard compounding pharmacy access is legally uncertain in the US.
What Is the Best Place to Buy AOD-9604?
Peptide-specialist research suppliers that publish third-party HPLC reports confirming at least 98% purity, mass spectrometry verification of the 1815.1 Da molecular weight, and endotoxin testing results are the most defensible sourcing option. Buying from suppliers without full COA data is the single biggest quality risk in this market.Table of Contents
- What exactly is AOD-9604?
- What does the clinical evidence actually show?
- How does AOD-9604 work at the molecular level?
- What makes a sourcing option legitimate?
- How do I read a COA for AOD-9604?
- What most pages get wrong about buying AOD-9604
- How does AOD-9604 compare to real alternatives?
- Storage, reconstitution, and the chemistry behind the rules
- Legal and regulatory reality in 2026
- FAQ
- Sources
What Exactly Is AOD-9604?
AOD-9604 (Anti-Obesity Drug 9604) is a synthetic peptide corresponding to residues 177 to 191 of human growth hormone, with a tyrosine residue added at the N-terminus to make it a 16-mer. It retains the disulfide bond between Cys182 and Cys189 that is present in intact GH. The molecular formula is C78H123N23O23S2 and the molecular weight is approximately 1815.1 Da. These are the verifiable numbers to check on any COA.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →The peptide was developed by Metabolic Pharmaceuticals (Melbourne, Australia) specifically to isolate the fat-metabolism activity of the GH C-terminal domain while avoiding the growth-promoting and insulin-sensitizing effects of full-length GH.
What Does the Clinical Evidence Actually Show?
| Claim | Best Evidence Type | Effect Direction | Confidence |
|---|---|---|---|
| AOD-9604 promotes fat loss in obese humans | Phase 2 RCTs (Metabolic Pharmaceuticals; small n, short duration) | Mixed, some doses showed modest signal | Low |
| Does not elevate IGF-1 at studied doses | Phase 2 human trial safety data and animal studies | Favorable (no significant IGF-1 rise) | Moderate (for doses tested) |
| Does not cause insulin resistance | Animal studies, limited human phase 2 data | Favorable compared to HGH | Low to Moderate |
| Stimulates lipolysis via beta-3 adrenergic pathway | In vitro and animal mechanistic studies | Positive in animal adipocytes | Low (mechanism only; not proven in humans) |
| Cartilage repair or joint benefit | Animal models only | Possibly positive in rodent cartilage studies | Very Low |
| Safe for human subcutaneous injection at studied doses | Phase 2 data (limited populations, short term) | No serious adverse events reported in trials | Low (insufficient long-term data) |
Bottom line: The strongest evidence category for AOD-9604 is Phase 2 human trial data, which is better than most research peptides. However, those trials used specific doses in controlled populations over short windows and the compound did not reach Phase 3. Do not interpret Phase 2 data as proof of efficacy or safety at doses and durations beyond what was studied.
How Does AOD-9604 Work at the Molecular Level?
The C-terminal region of human growth hormone (roughly residues 177 to 191) does not bind the classical GH receptor (GHR) in the same way full-length GH does. GH binds GHR via two binding sites (Site 1 and Site 2). The C-terminal fragment lacks Site 1 binding affinity. This structural difference is the mechanistic basis for the claim that AOD-9604 avoids GH-like growth and IGF-1 stimulating effects.
Proposed lipolytic mechanism: In vitro and rodent studies suggest the fragment activates beta-3 adrenergic receptors in adipocytes, promoting cyclic AMP accumulation and downstream hormone-sensitive lipase activation. Animal studies also suggest inhibition of lipogenesis via acetyl-CoA carboxylase modulation. These are plausible pathway-level mechanisms. What they do NOT prove: that these effects translate to meaningful fat loss in humans at any specific dose, or that they occur at comparable magnitude in human visceral versus subcutaneous adipose tissue.
The disulfide bond between Cys182 and Cys189 is critical for the peptide's three-dimensional conformation and biological activity. Reduction of this bond (which occurs under oxidizing or improperly buffered storage conditions) would destroy activity. This is one reason peptide purity and storage matter beyond simple contamination concerns.
What Makes a Sourcing Option Legitimate?
The research peptide market has no mandatory pre-market testing requirement for products sold as "not for human use." That means quality is entirely self-declared unless a supplier commissions independent third-party testing. The following criteria separate defensible suppliers from commodity vendors:
- Third-party HPLC purity report: At least 98% purity with an actual chromatogram showing the retention time peak and integration, not just a stated number.
- Mass spectrometry (MS) confirmation: The observed mass should be consistent with the expected 1815.1 Da molecular weight. Adducts (e.g., [M+2H]2+) are normal on LCMS reports. Know what you are reading or ask the supplier to annotate the spectrum.
- Endotoxin testing: Bacterial endotoxins cause fever and systemic reactions at very low concentrations. Research-grade peptides should report endotoxin levels, ideally below 1 EU/mg by the Limulus Amebocyte Lysate (LAL) method.
- Amino acid composition or sequence confirmation: Some suppliers add this; it provides an additional layer of identity verification beyond mass alone.
- Batch-specific COAs: A COA should carry a lot number that matches the vial you receive. Generic PDFs that apply to all batches are not meaningful quality evidence.
How Do I Read a COA for AOD-9604?
A certificate of analysis is only as good as the lab that produced it and the data it contains. Here is what to look for, line by line:
| COA Field | What to Look For | Red Flag |
|---|---|---|
| Product name / sequence | Should match the known 16-mer sequence with N-terminal Tyr and disulfide bond noted | Generic "HGH fragment" label with no sequence detail |
| Molecular weight observed | Near 1815.1 Da (or consistent adduct on MS) | Wrong molecular weight or no MS data at all |
| HPLC purity % | At least 98%; chromatogram attached | Purity stated but no chromatogram provided |
| Endotoxin | Below 1 EU/mg by LAL method | Field left blank or "not tested" |
| Lot number | Must match the vial label you receive | No lot number, or lot not traceable to your order |
| Testing lab | Named independent third-party lab, not internal only | In-house testing only with no external verification |
| Moisture / water content | Lower moisture indicates better lyophilization | Not always required but its absence is a minor flag |
What Most Pages Get Wrong About Buying AOD-9604
This is the section commodity medspa blogs skip entirely.
1. Penetration and bioavailability limits are almost never discussed. AOD-9604 is a 16-amino-acid peptide with a molecular weight over 1800 Da. At that size, transdermal delivery through intact skin is essentially negligible by passive diffusion. If a vendor sells an AOD-9604 "cream" or "serum" and claims systemic or deep-tissue lipolytic effect through topical application, that claim has no credible mechanistic or clinical support. Research use involves subcutaneous injection, which is the route used in all clinical trials.
2. "FDA approved" is misused constantly. AOD-9604 was granted FDA IND (Investigational New Drug) status, which is not approval. IND status is the starting point for clinical trials, not the endpoint. Several pages imply or state that IND status means some level of FDA endorsement. It does not.
3. Compounding pharmacy availability is legally contested. The FDA's 2015 and subsequent guidance documents have questioned whether AOD-9604 qualifies as a bulk substance under 503A compounding rules, because it is not a component of an FDA-approved drug with the same active ingredient. Access through US compounding pharmacies is therefore legally uncertain, not routine.
4. The disulfide bond issue is ignored. Many pages treat AOD-9604 as a simple linear peptide. The Cys182-Cys189 disulfide bond means the peptide is sensitive to reducing agents (like vitamin C in aqueous solution, dithiothreitol, or glutathione). Storing reconstituted AOD-9604 in a solution that contains reducing compounds or at alkaline pH will degrade the disulfide bond and destroy bioactivity, regardless of whether the peptide looks visually clear.
How Does AOD-9604 Compare to Real Alternatives?
| Compound | Mechanism | Human Trial Evidence | Regulatory Status (US) | Where AOD-9604 Loses |
|---|---|---|---|---|
| AOD-9604 | GH C-terminal fragment; proposed beta-3 adrenergic lipolysis | Phase 2 (small, short) | Research compound; compounding legally uncertain | No Phase 3 data; access difficult |
| Semaglutide (Ozempic/Wegovy) | GLP-1 receptor agonist; appetite and gastric motility | Multiple large Phase 3 RCTs (thousands of patients) | FDA approved for obesity (Wegovy) | AOD-9604 loses badly on evidence volume and regulatory clarity |
| Tirzepatide (Zepbound) | Dual GIP/GLP-1 agonist | Phase 3 RCTs with robust weight loss endpoints | FDA approved for obesity | AOD-9604 loses on effect size and evidence quality |
| CJC-1295/Ipamorelin (combo) | GHRH analogue plus ghrelin mimetic; raises GH pulse | Limited Phase 1/2 data for CJC-1295 alone | Research compound | AOD-9604 may have better safety profile (no IGF-1 rise); tie on evidence quality |
| Tesamorelin | GHRH analogue; raises GH and IGF-1 | Phase 3 RCTs in HIV-associated lipodystrophy | FDA approved (Egrifta, narrow indication) | AOD-9604 loses on regulatory standing; tesamorelin has more robust evidence |
The honest summary: if fat loss is the clinical goal, GLP-1 receptor agonists are supported by orders of magnitude more human evidence than AOD-9604. AOD-9604's theoretical advantage (no IGF-1 elevation, no growth promotion) matters mainly as a safety argument, not an efficacy argument.
Storage, Reconstitution, and the Chemistry Behind the Rules
Why store lyophilized peptides frozen? Lyophilization removes water and slows hydrolysis of peptide bonds, but does not stop it entirely. At room temperature, residual moisture in the lyophilized cake catalyzes slow hydrolysis. Freezing at minus 20 degrees Celsius reduces reaction rates substantially (Arrhenius kinetics: roughly a 2- to 3-fold rate reduction per 10 degrees Celsius drop). For AOD-9604 specifically, the disulfide bond is also susceptible to oxidation at warmer temperatures if any oxygen is present.
Why bacteriostatic water, not sterile water? Bacteriostatic water contains 0.9% benzyl alcohol, which inhibits microbial growth after the vial is punctured. A peptide vial reconstituted with plain sterile water should ideally be used within 24 to 48 hours because there is no preservative. With bacteriostatic water, use within 28 days refrigerated is a standard working guideline, though stability data for AOD-9604 specifically at this window is not publicly peer-reviewed. When in doubt, use sooner rather than later.
Why swirl, never shake? Vigorous shaking introduces air-water interfaces that can cause peptide aggregation through surface denaturation. The disulfide bond in AOD-9604 makes proper folding even more important; aggregated or misfolded peptide has reduced or zero biological activity and cannot be detected by eye alone. The solution will still look clear.
Why avoid vitamin C in the same solution? Ascorbic acid is a reducing agent. It donates electrons readily, which can reduce (break) disulfide bonds. A broken Cys182-Cys189 disulfide in AOD-9604 would linearize the peptide and abolish the conformation required for receptor interaction. This is chemistry, not product-brand preference.
Legal and Regulatory Reality in 2026
AOD-9604 occupies an ambiguous legal space in most jurisdictions. Key points by region:
- United States: Not FDA approved. Can be sold as a research chemical. Compounding pharmacy access is contested under FDA bulk substance guidance. Possession for personal use is a gray area; sale for human administration without a prescription would violate the Federal Food, Drug, and Cosmetic Act.
- Australia: Classified as a prescription medicine by the Therapeutic Goods Administration (TGA) under Schedule 4. Cannot be legally sold without a prescription.
- European Union: Not approved under EMA. Status varies by member state but generally falls under unlicensed medicine rules.
- Sport: WADA prohibits AOD-9604 under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) regardless of jurisdiction. This applies in-competition and out-of-competition.
FAQ
Sources
- Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Hormone Research. 2000;53(6):274-278.
- Heffernan MA, Jiang WJ, Thorburn AW, Ng FM. Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism. American Journal of Physiology Endocrinology and Metabolism. 2000;279(3):E501-E507.
- Metabolic Pharmaceuticals Ltd. Clinical trial summary data for AOD9604 Phase 2 obesity studies. Publicly referenced in Australian TGA submissions and company investor reports, early 2000s.
- World Anti-Doping Agency. Prohibited List 2024. Section S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics. wada-ama.org.
- US Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act. FDA Docket, various updates 2015 onward.
- Therapeutic Goods Administration (Australia). Prescription medicines: scheduling of human growth hormone fragments including AOD-9604. TGA scheduling decisions.
- De Meyts P. The structural basis of insulin and insulin-like growth factor-I receptor activation and allosteric inhibition. Vitamins and Hormones. 2008;80:1-51. (Context for GH receptor binding site differences.)
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharmaceutical Research. 2010;27(4):544-575. (Peptide hydrolysis and disulfide chemistry context.)
- United States Pharmacopeia. Chapter 85: Bacterial Endotoxins Test. USP-NF. (LAL method endotoxin standards.)
- Wilkinson DJ. A review of the molecular characteristics of growth hormone peptide fragments and their clinical relevance. Journal of Peptide Science. Published literature reviewed 2010 to 2020 range.